Wing Lindon M H, Reid Christopher M, Ryan Philip, Beilin Lawrence J, Brown Mark A, Jennings Garry L R, Johnston Colin I, McNeil John J, Macdonald Graham J, Marley John E, Morgan Trefor O, West Malcolm J
School of Medicine, Flinders University, Adelaide, Australia.
N Engl J Med. 2003 Feb 13;348(7):583-92. doi: 10.1056/NEJMoa021716.
Treatment of hypertension with diuretics, beta-blockers, or both leads to improved outcomes. It has been postulated that agents that inhibit the renin-angiotensin system confer benefit beyond the reduction of blood pressure alone. We compared the outcomes in older subjects with hypertension who were treated with angiotensin-converting-enzyme (ACE) inhibitors with the outcomes in those treated with diuretic agents.
We conducted a prospective, randomized, open-label study with blinded assessment of end points in 6083 subjects with hypertension who were 65 to 84 years of age and received health care at 1594 family practices. Subjects were followed for a median of 4.1 years, and the total numbers of cardiovascular events in the two treatment groups were compared with the use of multivariate proportional-hazards models.
At base line, the treatment groups were well matched in terms of age, sex, and blood pressure. By the end of the study, blood pressure had decreased to a similar extent in both groups (a decrease of 26/12 mm Hg). There were 695 cardiovascular events or deaths from any cause in the ACE-inhibitor group (56.1 per 1000 patient-years) and 736 cardiovascular events or deaths from any cause in the diuretic group (59.8 per 1000 patient-years; the hazard ratio for a cardiovascular event or death with ACE-inhibitor treatment was 0.89 [95 percent confidence interval, 0.79 to 1.00]; P=0.05). Among male subjects, the hazard ratio was 0.83 (95 percent confidence interval, 0.71 to 0.97; P=0.02); among female subjects, the hazard ratio was 1.00 (95 percent confidence interval, 0.83 to 1.21; P=0.98); the P value for the interaction between sex and treatment-group assignment was 0.15. The rates of nonfatal cardiovascular events and myocardial infarctions decreased with ACE-inhibitor treatment, whereas a similar number of strokes occurred in each group (although there were more fatal strokes in the ACE-inhibitor group).
Initiation of antihypertensive treatment involving ACE inhibitors in older subjects, particularly men, appears to lead to better outcomes than treatment with diuretic agents, despite similar reductions of blood pressure.
使用利尿剂、β受体阻滞剂或两者联合治疗高血压可改善预后。据推测,抑制肾素 - 血管紧张素系统的药物除了单纯降低血压外还能带来益处。我们比较了老年高血压患者接受血管紧张素转换酶(ACE)抑制剂治疗与接受利尿剂治疗的预后情况。
我们进行了一项前瞻性、随机、开放标签研究,对6083名年龄在65至84岁、在1594家家庭诊所接受医疗服务的高血压患者进行终点的盲法评估。对受试者进行了中位数为4.1年的随访,并使用多变量比例风险模型比较了两个治疗组中心血管事件的总数。
在基线时,治疗组在年龄、性别和血压方面匹配良好。到研究结束时,两组血压下降程度相似(下降26/12 mmHg)。ACE抑制剂组有695例心血管事件或任何原因导致的死亡(每1000患者年56.1例),利尿剂组有736例心血管事件或任何原因导致的死亡(每1000患者年59.8例;ACE抑制剂治疗的心血管事件或死亡的风险比为0.89 [95%置信区间,0.79至1.00];P = 0.05)。在男性受试者中,风险比为0.83(95%置信区间,于0.71至0.97;P = 0.02);在女性受试者中,风险比为1.00(95%置信区间,0.83至1.21;P = 0.98);性别与治疗组分配之间相互作用的P值为0.15。非致命性心血管事件和心肌梗死的发生率随ACE抑制剂治疗而降低,而每组中风发生数量相似(尽管ACE抑制剂组致命性中风更多)。
在老年受试者,尤其是男性中,开始使用ACE抑制剂进行抗高血压治疗似乎比使用利尿剂治疗能带来更好的预后,尽管血压降低程度相似。